Compare WST & TROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WST | TROW |
|---|---|---|
| Founded | 1923 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 22.6B |
| IPO Year | N/A | N/A |
| Metric | WST | TROW |
|---|---|---|
| Price | $275.03 | $104.22 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 10 | 11 |
| Target Price | ★ $346.78 | $106.45 |
| AVG Volume (30 Days) | 742.7K | ★ 2.0M |
| Earning Date | 10-23-2025 | 02-04-2026 |
| Dividend Yield | 0.32% | ★ 4.92% |
| EPS Growth | 0.17 | ★ 0.40 |
| EPS | 6.75 | ★ 9.17 |
| Revenue | $3,017,900,000.00 | ★ $7,205,200,000.00 |
| Revenue This Year | $7.01 | $5.40 |
| Revenue Next Year | $6.20 | $5.44 |
| P/E Ratio | $40.37 | ★ $11.27 |
| Revenue Growth | ★ 4.92 | 4.25 |
| 52 Week Low | $187.43 | $77.85 |
| 52 Week High | $348.90 | $118.32 |
| Indicator | WST | TROW |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 53.88 |
| Support Level | $264.92 | $102.58 |
| Resistance Level | $275.56 | $106.06 |
| Average True Range (ATR) | 7.64 | 2.06 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 53.72 | 53.03 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of September, the firm had $1.767 trillion in managed assets, composed of equity (50%), balanced (35%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two-thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.